BiosimilarBiological
TK-006 clinical trials
Also written TK006.
A product of Denosumab; its studies count on that page too.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses TK-006 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone MetastasesStatus unknownPhase 1Jiangsu T-Mab Biopharma Co.,LtdNCT03487055Written as TK006
- Assessment of Anti-RANKL Antibody in Post-menopausal WomenStatus unknownPhase 1Jiangsu T-Mab Biopharma Co.,LtdNCT03242512Written as TK006
- Assessment of TK006 in Patients With Breast Cancer-related Bone MetastasesStatus unknownPhase 1Jiangsu T-Mab Biopharma Co.,LtdNCT03239756Written as TK006